Kara G Marson1, Robert Marlin2, Phong Pham3, Stephanie E Cohen4, Diane Jones5, Marguerite Roemer3, Philip J Peters6, Barbara Haller3, Christopher D Pilcher5. 1. Division of HIV, Infectious Diseases and Global Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA, United States. Electronic address: kara.marson@ucsf.edu. 2. Department of Medicine, University of California, San Diego, United States. 3. Zuckerberg San Francisco General Hospital Clinical Laboratory, United States. 4. San Francisco Department of Public Health, United States. 5. Division of HIV, Infectious Diseases and Global Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA, United States. 6. Division of HIV/AIDS Prevention, US Centers for Disease Control and Prevention, Atlanta, GA, United States.
Abstract
BACKGROUND: Our medical center laboratory recently adapted its 24/7, two-hourly testing program to use an ARCHITECT-Multispot-viral load (AR-MS-VL) algorithm in place of a previous rapid test-immunofluorescence (RT-IF) algorithm. OBJECTIVES: We evaluated screening test performance, acute case detection, turnaround time and ability to resolve HIV status under the new algorithm. STUDY DESIGN: We considered consecutive HIV tests from January to November 2015. AR-MS-VL results at Zuckerberg San Francisco General Hospital and Trauma Center (ZSFG) were compared with RT-IF results at ZSFG and also with AR-MS-VL results in the recently completed CDC Screening Targeted Populations to Interrupt On-going Chains of HIV Transmission with Enhanced Partner Notification (STOP) Study for targeted testing of MSM at publicly funded testing sites in San Francisco. RESULTS: Among 21,985 HIV tests performed at ZSFG, 16,467 were tested by RT-IF and 5518 by AR-MS-VL. There were 321 HIV infections detected, of which 274 (84%) were known HIV+ cases, and 47 were newly identified HIV infections. Considering only patients of HIV-negative or -unknown status, prevalence was 0.22%. Under the AR-MS-VL algorithm, turnaround times for screening results and full algorithm results were 3 and 21h; status-unresolved cases were reduced (from 47% to 22%) compared with the RT-IF algorithm. The positive predictive value (PPV) of a new-positive AR screening test was low (0.44) at ZSFG, where no acute infections were detected. At STOP Study sites where HIV prevalence was higher and acute infection was more common, the AR PPV was higher (0.93). All 24 false-positive AR screening tests at ZSFG had a signal/cutoff (S/CO) ratio of <15 and all 88 true-positive tests had S/CO ratio >15. Of 62 acute infections in the STOP Study, 23 (37%) had an S/CO<15. DISCUSSION: An AR-MS-VL algorithm is feasible and can return rapid results in a large medical center. In this setting, reactive 4th generation assay tests that are negative for HIV antibodies are typically false-positive with low S/CO ratios.
BACKGROUND: Our medical center laboratory recently adapted its 24/7, two-hourly testing program to use an ARCHITECT-Multispot-viral load (AR-MS-VL) algorithm in place of a previous rapid test-immunofluorescence (RT-IF) algorithm. OBJECTIVES: We evaluated screening test performance, acute case detection, turnaround time and ability to resolve HIV status under the new algorithm. STUDY DESIGN: We considered consecutive HIV tests from January to November 2015. AR-MS-VL results at Zuckerberg San Francisco General Hospital and Trauma Center (ZSFG) were compared with RT-IF results at ZSFG and also with AR-MS-VL results in the recently completed CDC Screening Targeted Populations to Interrupt On-going Chains of HIV Transmission with Enhanced Partner Notification (STOP) Study for targeted testing of MSM at publicly funded testing sites in San Francisco. RESULTS: Among 21,985 HIV tests performed at ZSFG, 16,467 were tested by RT-IF and 5518 by AR-MS-VL. There were 321 HIV infections detected, of which 274 (84%) were known HIV+ cases, and 47 were newly identified HIV infections. Considering only patients of HIV-negative or -unknown status, prevalence was 0.22%. Under the AR-MS-VL algorithm, turnaround times for screening results and full algorithm results were 3 and 21h; status-unresolved cases were reduced (from 47% to 22%) compared with the RT-IF algorithm. The positive predictive value (PPV) of a new-positive AR screening test was low (0.44) at ZSFG, where no acute infections were detected. At STOP Study sites where HIV prevalence was higher and acute infection was more common, the AR PPV was higher (0.93). All 24 false-positive AR screening tests at ZSFG had a signal/cutoff (S/CO) ratio of <15 and all 88 true-positive tests had S/CO ratio >15. Of 62 acute infections in the STOP Study, 23 (37%) had an S/CO<15. DISCUSSION: An AR-MS-VL algorithm is feasible and can return rapid results in a large medical center. In this setting, reactive 4th generation assay tests that are negative for HIV antibodies are typically false-positive with low S/CO ratios.
Authors: Patrick S Sullivan; Michael S Lyons; Maggie Czarnogorski; Bernard M Branson Journal: Public Health Rep Date: 2016 Jan-Feb Impact factor: 2.792
Authors: Monique Glover Rucker; Rebecca Eavou; Kristi L Allgood; Donna Sinclair; Rukiyat Lawal; Audra Tobin; David Pitrak; Nancy R Glick Journal: Public Health Rep Date: 2016 Jan-Feb Impact factor: 2.792
Authors: Tuan Le; Edwina J Wright; Davey M Smith; Weijing He; Gabriel Catano; Jason F Okulicz; Jason A Young; Robert A Clark; Douglas D Richman; Susan J Little; Sunil K Ahuja Journal: N Engl J Med Date: 2013-01-17 Impact factor: 91.245
Authors: Rebecca V Liddicoat; Nicholas J Horton; Renata Urban; Elizabeth Maier; Demian Christiansen; Jeffrey H Samet Journal: J Gen Intern Med Date: 2004-04 Impact factor: 5.128
Authors: Katerina A Christopoulos; Nicola M Zetola; Jeffrey D Klausner; Barbara Haller; Brian Louie; C Bradley Hare; Mark Pandori; Patricia Nassos; Marguerite Roemer; Christopher D Pilcher Journal: J Acquir Immune Defic Syndr Date: 2013-02-01 Impact factor: 3.731
Authors: Kara I Geren; Frank Lovecchio; Jason Knight; Robert Fromm; Eric Moore; Cheri Tomlinson; André Valdez; Dan Hobohm; J Stephan Stapczynski Journal: Ann Emerg Med Date: 2014-06-23 Impact factor: 5.721
Authors: Philip J Peters; Emily Westheimer; Stephanie Cohen; Lisa B Hightow-Weidman; Nicholas Moss; Benjamin Tsoi; Laura Hall; Charles Fann; Demetre C Daskalakis; Steve Beagle; Pragna Patel; Asa Radix; Evelyn Foust; Robert P Kohn; Jenni Marmorino; Mark Pandori; Jie Fu; Taraz Samandari; Cynthia L Gay Journal: JAMA Date: 2016-02-16 Impact factor: 56.272
Authors: Marc A Pitasi; Shilpa N Patel; Laura G Wesolowski; Silvina Masciotra; Wei Luo; S Michele Owen; Kevin P Delaney Journal: Sex Transm Dis Date: 2020-05 Impact factor: 3.868